Literature DB >> 20014890

Biomarkers for prostate cancer detection.

Amanda Beth Reed1, Dipen J Parekh.   

Abstract

Since its approval by the US FDA in 1986, prostate-specific antigen (PSA) has been employed to monitor men with a diagnosis of prostate cancer. In 1994, PSA was approved for use in prostate cancer screening and has been employed worldwide. However, due to the limited specificity of PSA for the disease, novel biomarkers are needed for detecting prostate cancer and for determining which cancers need to be treated. This review will discuss the development of new biomarkers for prostate cancer detection and disease prognostication, focusing on recent progress and particular topical issues related to the development and validation of these new markers.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20014890     DOI： 10.1586/era.09.168

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN： 1473-7140            Impact factor:   4.512


  12 in total

Review 1.  Opportunities and challenges facing biomarker development for personalized head and neck cancer treatment.

Authors:  Alexandra Lucs; Benjamin Saltman; Christine H Chung; Bettie M Steinberg; David L Schwartz
Journal:  Head Neck       Date:  2012-01-27       Impact factor: 3.147

2.  Prostate-specific antigen: its relationship with alcohol intake and tobacco.

Authors:  Jorge D Escandriolo Nackauzi; Raúl H Colla; Graciela R Ravazzani; María I Gaido; Patricia Bertolotto; Adriana B Actis
Journal:  Med Oncol       Date:  2011-04-12       Impact factor: 3.064

3.  Clinical and oncological outcomes of robot-assisted radical prostatectomy with nerve sparing vs. non-nerve sparing for high-risk prostate cancer cases.

Authors:  Kiyoshi Takahara; Makoto Sumitomo; Kosuke Fukaya; Takahito Jyoudai; Masashi Nishino; Masaru Hikichi; Kenji Zennami; Takuhisa Nukaya; Manabu Ichino; Naohiko Fukami; Hitomi Sasaki; Mamoru Kusaka; Ryoichi Shiroki
Journal:  Oncol Lett       Date:  2019-07-31       Impact factor: 2.967

4.  Proteomic analysis of microvesicles released by the human prostate cancer cell line PC-3.

Authors:  Kirsten Sandvig; Alicia Llorente
Journal:  Mol Cell Proteomics       Date:  2012-03-28       Impact factor: 5.911

5.  What we have learned from randomized trials of prostate cancer screening.

Authors:  Richard M Hoffman; Anthony Y Smith
Journal:  Asian J Androl       Date:  2011-04-11       Impact factor: 3.285

6.  Extramammary Paget's diseases in men from the Shanghai area: its association with PSA level increase.

Authors:  Guohai Shi; Ding-Wei Ye; Xudong Yao; Shiling Zhang; Bo Dai; Hailiang Zhang; Yijun Shen; Yao Zhu; Yiping Zhu; Wenjun Xiao; Chunguang Ma
Journal:  APMIS       Date:  2010-10       Impact factor: 3.205

7.  Current Challenges in Prostate Cancer Management and the Rationale behind Targeted Focal Therapy.

Authors:  Al B Barqawi; Kevin J Krughoff; Khadijah Eid
Journal:  Adv Urol       Date:  2012-05-10

8.  The emergence of extracellular vesicles in urology: fertility, cancer, biomarkers and targeted pharmacotherapy.

Authors:  Andrew J Tompkins; Devasis Chatterjee; Michael Maddox; Justin Wang; Emily Arciero; Giovanni Camussi; Peter J Quesenberry; Joseph F Renzulli
Journal:  J Extracell Vesicles       Date:  2015-06-30

9.  The role of targeted focal therapy in the management of low-risk prostate cancer: update on current challenges.

Authors:  Daniel W Smith; Diliana Stoimenova; Khadijah Eid; Al Barqawi
Journal:  Prostate Cancer       Date:  2012-12-31

10.  Evaluation of prediction models for the staging of prostate cancer.

Authors:  Susie Boyce; Yue Fan; Ronald William Watson; Thomas Brendan Murphy
Journal:  BMC Med Inform Decis Mak       Date:  2013-11-15       Impact factor: 2.796
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.